Sanofi Tumbled Over 17% in Morning Trading After It Expects Business EPS to Be Roughly Flat in 2024
Tiger Newspress2023-10-27
Sanofi SA tumbled over 17% in morning trading.
It expects business EPS to be roughly flat in 2024 compared with this year due to increased research-and-development investment and a strong rebound in 2025.
Meanwhile, it plans to separate its consumer health division, probably through a spinoff, as the French drugmaker deepens its focus on cutting-edge medicines and vaccines.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.